Source: Virtual Congress 2020 – Diagnosis and management of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Gendron (Mississauga, Canada), N. Sriskandarajah (Mississauga, Canada), K. Johnston (Vancouver, Canada), K. Osenenko (Vancouver, Canada), S. Noorduyn (Mississauga, Canada). Real-world treatment patterns of benralizumab therapy for patients with severe asthma. 4646

Member's Comments

No comment yet.

Related content which might interest you: Real-world oral glucocorticoid-sparing effect of benralizumab in severe asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 The cost-efficacy of combined anti-inflammatory therapy in the treatment of children in severe persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003 Real-world treatment patterns of newly diagnosed patients with asthma and/or COPD Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 The response to combination therapy treatment regimens in severe/difficult-to-treat asthma Source: Eur Respir J 2008; 32: 1237-1242 Year: 2008 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Two therapy option in patients with uncontrolled asthma Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Multicolored magnetic-laser therapy in asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 510s Year: 2004 Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Effectiveness of combined therapy in patients with brittle asthma Source: Eur Respir J 2002; 20: Suppl. 38, 512s Year: 2002